Tetraphase deal done, La Jol­la Phar­ma­ceu­ti­cal taps Lar­ry Ed­wards as CEO; Long­time Eli Lil­ly ex­ec Michael Over­dorf heads to An­nex­on as CBO

→ As La Jol­la Phar­ma­ceu­ti­cal closed on their ac­qui­si­tion of Tetraphase on Wednes­day, the San Diego biotech al­so an­nounced that they’re tak­ing the pres­i­dent and CEO right along with them as Lar­ry Ed­wards steps in. Ed­wards, who had a 15-year run at Mer­ck and was a glob­al mar­ket­ing di­rec­tor for the phar­ma gi­ant, spent the last year at the helm at Tetraphase and 5 years over­all in oth­er roles.

Last No­vem­ber, George Tid­marsh walked away as La Jol­la’s top ex­ec “to pur­sue oth­er in­ter­ests” af­ter their drug LJPC-401 flamed out for be­ta tha­lassemia pa­tients and the study (LJ401-BT01) was sum­mar­i­ly scrapped.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.